SCHEMBL6091230

SCHEMBL6091230

COC(=O)[C@H](CC1(C)CC1)NC(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KYNU Q16719 1/20 0.59
ALDH1A1 P00352 5/20 0.57
ALOX15 P16050 1/20 0.57
CYP3A4 P08684 6/20 0.54
TSHR P16473 6/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPT P10636 1/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CTSK P43235 3/20 0.53
CASP1 P29466 1/20 0.53
CTSS P25774 2/20 0.52
CTSL P07711 1/20 0.52
CTSB P07858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091228 1.00 KYNU (0.59) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL2396183 0.95 KYNU (0.57) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL2398018 0.95 KYNU (0.57) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL3617397 0.94 KYNU (0.56) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL3824400 0.94 KYNU (0.56) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL25240531 0.93 CTSK (0.52) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL25288547 0.93 CTSK (0.52) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL18686857 0.91 CTSK (0.50) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL24112557 0.91 CTSK (0.50) KYNUALDH1A1ALOX15CYP3A4TSHR
SCHEMBL2399710 0.88 CTSK (0.50) KYNUALDH1A1ALOX15CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. 2024-12-05 US disclosed
US-12060333-B2 Aminocarbamoyl compounds for the treatment of viral infections HOFFMANN-LA ROCHE INC. (US) 2024-08-13 US disclosed
EP-4380920-A1 INHIBITORS FOR CORONAVIRUSES Cocrystal Pharma, Inc. (US) 2024-06-12 EP disclosed
EP-4204393-A1 AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2023-07-05 EP disclosed
WO-2023014758-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. (US) 2023-02-09 WO disclosed
WO-2022043374-A1 AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2022-03-03 WO disclosed
US-20060287402-A1 Cathepsin inhibitors MERCK FROSST CANADA & CO. (CA) 2006-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES ACE, ACE2, SARS1 KYNU 3189/4885ALDH1A1 1784/4885ALOX15 2006/4885
US-12060333-B2 Aminocarbamoyl compounds for the treatment of viral infections SARS1, BCAT1, SLC1A5 KYNU 1834/4885ALDH1A1 2749/4885ALOX15 2482/4885
US-20060287402-A1 Cathepsin inhibitors CTSB, CTSK, CTSS KYNU 1454/4885ALDH1A1 2983/4885ALOX15 2746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.